doi:10.19982/j.issn.1000-6621.20220130

Abstract

CLC Number:

Figures/Tables 1

References 15

[1]	中华医学会血液学分会血栓与止血学组. 成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版). 中华血液学杂志, 2020, 41(8):617-623. doi: 10.3760/cma.j.issn.0253-2727.2020.08.001. doi: 10.3760/cma.j.issn.0253-2727.2020.08.001
[2]	Vayne C, Guéry EA, Rollin J, et al. Pathophysiology and Diagnosis of Drug-Induced Immune Thrombocytopenia. J Clin Med, 2020, 9(7):2212. doi: 10.3390/jcm9072212. doi: 10.3390/jcm9072212 URL
[3]	Bakchoul T, Marini I. Drug-associated thrombocytopenia. Hematology Am Soc Hematol Educ Program, 2018, 2018(1):576-583. doi: 10.1182/asheducation-2018.1.576. doi: 10.1182/asheducation-2018.1.576 pmid: 30504360
[4]	卢志军, 杨瑾. 1例利福平致严重血小板减少并脑出血死亡的分析. 今日药学, 2019, 29(5):350-352. doi: 10.12048/j.issn.1674-229X.2019.05.14. doi: 10.12048/j.issn.1674-229X.2019.05.14
[5]	Maurício J, Flor-de-Lima B, Pacheco P. Severe rifampicin-induced thrombocytopenia in a patient with miliary tuberculosis. Pulmonology, 2020, 26(4):247-249. doi: 10.1016/j.pulmoe.2019.09.005. doi: S2531-0437(19)30175-8 pmid: 31722846
[6]	徐燕, 傅胜, 李琴, 等. 药源性血小板减少症导致1例死亡病例分析. 世界最新医学信息文摘, 2019, 19(42):239,246. doi: 10.19613/j.cnki.1671-3141.2019.42.138. doi: 10.19613/j.cnki.1671-3141.2019.42.138
[7]	孙平, 吴广胜, 梁迅. RITP患者血浆中利福平依赖性抗血小板抗体的特性及其作用机制. 解放军医学杂志, 2017, 42(5):413-419. doi: 10.11855/j.issn.0577-7402.2017.05.10. doi: 10.11855/j.issn.0577-7402.2017.05.10
[8]	Lugito NPH, Lorens JO, Kwenandar J, et al. The dilemma in a case of immune thrombocytopenia in a patient with human immunodeficiency virus on antituberculosis treatment for miliary pulmonary tuberculosis. Oxf Med Case Reports, 2019, 2019(11):486-489. doi: 10.1093/omcr/omz119. doi: 10.1093/omcr/omz119 URL
[9]	MacDougall KN, Parylo S, Sokoloff AA. Case of Vancomycin-Induced Immune Thrombocytopenia. Cureus, 2020, 12(5):e7940. doi: 10.7759/cureus.7940. doi: 10.7759/cureus.7940
[10]	Thaler J, Ay C, Gleixner KV, et al. Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). J Thromb Haemost, 2021, 19(7):1819-1822. doi: 10.1111/jth.15346. doi: 10.1111/jth.15346 URL
[11]	Cooper N, Ghanima W. Immune Thrombocytopenia. N Engl J Med, 2019, 381(10):945-955. doi: 10.1056/NEJMcp1810479. doi: 10.1056/NEJMcp1810479 URL
[12]	Chen G, He JQ. Rifampicin-induced disseminated intravascular coagulation in pulmonary tuberculosis treatment: A case report and literature review. Medicine, 2017, 96(7):e6135. doi: 10.1097/MD.0000000000006135. doi: 10.1097/MD.0000000000006135 URL
[13]	Havey TC, Cserti-Gazdewich C, Sholzberg M, et al. Recurrent disseminated intravascular coagulation caused by intermittent dosing of rifampin. Am J Trop Med Hyg, 2012, 86(2):264-267. doi: 10.4269/ajtmh.2012.11-0598. doi: 10.4269/ajtmh.2012.11-0598 URL
[14]	Hamad H, Sahu KK, Dunn S, et al. Rifampin Induced Thrombotic Thrombocytopenic Purpura. Indian J Hematol Blood Transfus, 2020, 36(3):575-577. doi: 10.1007/s12288-019-01249-9. doi: 10.1007/s12288-019-01249-9 URL
[15]	Abu-Sbeih H, Ali FS, Coronel E, et al. Safety of endoscopy in cancer patients with thrombocytopenia and neutropenia. Gastrointest Endosc, 2019, 89(5):937-949.e932. doi: 10.1016/j.gie.2018.12.004. doi: S0016-5107(18)33347-9 pmid: 30550744

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 15

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443.
[2]	Li Min, Yao Yushan, Qiao Haixia, Lei Hong. Association between pulmonary tuberculosis and the gut microbiota: treatment strategies [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 520-526.
[3]	Song Yunlin, Buzukela Abuduaini, Wang Guirong, Zhang Jiyuan, Lu Xiaobo. Research progresses on the role and mechanism of calcium-binding protein S100A12 and neutrophil extracellular trap formation in lung injury of severe pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 513-519.
[4]	Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415.
[5]	Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424.
[6]	An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438.
[7]	Li Leilei, Shi Lei, Wang Lin, Li Hongwei, Xu Liran, Pang Yu, Song Yanzheng. Clinical characteristics analysis of HIV-infected cases diagnosed with tuberculosis after surgery due to pulmonary nodules [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 266-273.
[8]	Gong Sheng, Wang Ning, Li Dan, Li Gang, Liu Yu, Jiang Liangshuang, Yao Xiaojun. Comparative study of fluorescence staining method and inflation-deflation method for thoracoscopic pulmonary tuberculosis segmentectomy [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 292-297.
[9]	Shi Yuru, Gu Dejian, Wu Jing, Liu Ting, Qin Linghan, Yue Li, Qi Yingjie. Diagnostic value of probe capture-based targeted next-generation sequencing and metagenomic next-generation sequencing for detecting Mycobacterium tuberculosis in bronchoalveolar lavage fluid [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 305-311.
[10]	Song Feier, Mao Yanjun, Xia Qiuyue, Zhou Yang, Lin Huan. The prevalence and influencing factors of post-tuberculosis lung disease: A Meta-analysis [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 322-330.
[11]	Yang Haixia, Zhang Xiaoyan, Huang Yi, Li Qiu. Effective and safety of concurrent intensity-modulated radiotherapy and anti-tuberculosis chemotherapy in patients with active pulmonary tuberculosis comorbid with thoracic tumor [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 312-321.
[12]	Li Xuelian, Zhang Hongyan, Wang Jun, Wang Qingfeng, Ma Liping, Chu Naihui, Nie Wenjuan. Safety of extended delamanid use in drug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 164-168.
[13]	Gao Li, Chen Shengyu, Zhang Wenqian, Li Dan, Zhang Guoqin. Investigation on ability of conducting tuberculosis surveillance among four types of high-risk population in Tianjin public hospitals [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 195-200.
[14]	Wang Dafu, Ma Xiaoxue, Wang Yun, Li Fudong, Rao Wen, Gong Tingting, Li Shijun, Li Jinlan. Analysis of risk factors for patient delay and adverse treatment outcomes among patients with pulmonary tuberculosis and diabetes mellitus in Guizhou Province, 2016—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 201-209.
[15]	Qiu Yong, Quan Zhuo, Qu Rong, Tian Fajun, Li Meng, Wang Gengsheng, Wang Ya, Guo Mingcheng, Gao Qian. Evaluation of different tuberculosis diagnostic tools for detecting patients in a primary-level clinic in rural China: a real-world retrospective study [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 181-188.